- Home
- INVA vs GLTO Comparison
INVA vs GLTO Comparison
Compare INVA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | GLTO |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVA | GLTO |
|---|---|---|
| Price | $22.39 | $28.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $36.50 | ★ $43.67 |
| AVG Volume (30 Days) | ★ 730.3K | 355.2K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $11.99 | N/A |
| P/E Ratio | $6.68 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $2.01 |
| 52 Week High | $25.15 | $38.33 |
Technical Indicators
Market Signals| Indicator | INVA | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 51.77 |
| Support Level | $19.16 | $24.53 |
| Resistance Level | $22.76 | $32.86 |
| Average True Range (ATR) | 0.71 | 2.50 |
| MACD | -0.23 | -0.30 |
| Stochastic Oscillator | 18.46 | 29.94 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.